

## References

I-253

1. Zynteglo (betibeglogene autotemcel) suspension for intravenous infusion [package insert]. Bluebird Bio, Inc., Somerville, MA. Revised 08/2022.
2. Clinical Pharmacology<sup>TM</sup> Compendium. 2024. Tampa FL: Gold Standard, Inc. Betibeglogene autotemcel.
3. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel gene therapy for Non- $\beta^0/\beta^0$  genotype  $\beta$ -thalassemia. *N Engl J Med*. 2022;386(5):415-427.
4. Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the  $\beta$ -hemoglobinopathies: the HGB-205 trial. *Nat Med*. 2022;28(1):81-88.
5. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent  $\beta$ -thalassemia. *N Engl J Med*. 2018;378(16):1479-1493.
6. Micromedex DrugDex Compendium®. 2024. Betibeglogene autotemcel.
7. Betibeglogene autotemcel. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 7, 2024.